ClinicalTrials.gg
Status unknownNCT04332302DIAPOWUpdated Oct 19, 2020

Power Strength Training in Type 2 Diabetic Mellitus Older Adults

An interventional study of Power resistance training in Diabetes Mellitus, Type 2 and Frailty, sponsored by Technical University of Madrid. Status unknown at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Technical University of Madrid · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Enrollment
361st of 383
41 · median 484
Started
2020
with 13 others
No phase
77 of 429
17 open now
Registered
306th of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 361st largest by enrollment of the 383 interventional ones that give a count, is one of 14 that started in 2020, is one of 77 with no phase, and was the 306th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

Diabetes is a disease with a high impact in the population older than 65 years old. Some indications suggest that diabetes in the old age aggravate the negative effects of ageing, as the loss of muscle mass and strength, bringing the patients to a situation of vulnerability and elevated risk of disability and death known as "frailty syndrome". Recently, scientists have observed that if older population train with musculation machines emphasising the muscular power, it is possible to have an impact on a disminution of frailty and restoring the physical functionality. This project deeps in the physiological and molecular mechanisms that underlie to improvements in the frail diabetic patients.

Read the detailed description

It is hypothesised that:

  1. High intensity training (strength-power) prescribed properly in an individualised form and supervised could influence significantly on the phenotypic response in the DM type 2: decreasing the level of clinical severity, disability and frailty, improving quality of life and glycaemic control, functional capacity and body composition (especially the muscle mass) of the diabetic patients (type 2) older than 65 years old.
  2. Part of the training adaptations in diabetic patients (type 2) older than 65 years old could due to physiological conditions as the systemic level of biomarkers as PDEF in these patients.
  3. Part of the training adaptations in diabetic patients (type 2) could be influenced by the characterisation of associated genes to the different types of DM type 2 recently characterised.

The principal aims are:

  1. To evaluate the effectiveness of a novel intervention based on strength-power exercise in individuals older than 65 years old with DM type 2 and frailty in term of: level of clinical severity, disability, glycaemic control, quality of life, functional capacity, state of frailty and body composition.
  2. To establish whether PDEF serves as diagnostic and prediction biomarker to training response, providing an objective and accessible method that would stratify the response to the intervention helping with the patients screening.
  3. To determine the role of characterised genetic variants in the different subgroups of DM type 2 in the level of response to the training stimuli.

Study design Longitudinal intervention stratified study, controlled and single-blinded, with a group of intervention and control group.

Based on data from a previous study recently published by the collaborators of this project. The sample size was calculated to get statistically significant differences in the physical functionality using ANCOVA and performing a bilateral contrast with alpha=0.05 of the effect of the group (with any of the independent variables), and it is needed 30 subjects by group (total n=60) to get a statistical power of 80%, with a partial eta ≥ 0.101 (value that corresponds with the size of the moderate effect).

Exercise program The intervention period will have a duration of 12 weeks, in which the training group will perform 2 sessions per week (24 sessions in total), while the control group will not perform any type of intervention, following their normal lifes and the habitual medical cares. The experimental group will perform a program focused on the muscle power training, in which there will be included exercise of upper limbs (chest press) and lower limbs (leg press). The exercises will be performed in muscle-building machines available in the reference institutions of the collaborators. It is important to point out that the intensity in the exercises will be individualised for any patient through a test of determination of muscle power validated previously by the consortium of researchers and the subjects will perform the exercises at this intensity at which the subjects will develop their maximal muscle performance, with the performance of 3-4 bouts of 8 repetitions in each exercise. After the third week of intervention, it will be put the attention to the speed of execution. The duration of each session has been estimated in 20-30 minutes.

Finally, the subjects in the control group will serve to compare the interventions with exercise and the clinical conventional treatment, as well as to determine whether the training program is able to restore the functional capacity in a similar way in diabetic patients without frailty.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Frailty

Keywords

  • Resistance Training
  • Quality of Life
  • Molecular Genetics
  • Skeletal Muscle
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign an .
  • Older than 65 years old with Type 2 Diabetes Mellitus diagnosed in a minimum of 2 previous years.
  • Being diagnosed frail, pre-frail or no frail.

Exclusion criteria

Exclusion Criteria:

  • Barthel's index lower than 60 points.
  • Incapacity to complete the SPPB fitness test.
  • Score lower than 20 points in the .
  • Cardiovascular event in the previous 6 months following the (NYHA) classification.
  • Patients clinically unstable by the investigator's judgement.
  • Terminal disease ( lower than 6 months).
  • Participation in another study that could interfere in the results of the current research.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Power training group

    Participants will be enrolled in a resistance training program.

    Other: Power resistance training

  • No intervention
    Control group

    Participants will be doing their normal life.

Interventions

  • OtherPower resistance training

    Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.

06

What researchers measure

Primary outcomes

  1. Change from Baseline Glycosylated Hemoglobin (Hemoglobin A1c) at 12 weeks

    Percentage

    Time frame: 0 and 12 weeks.

  2. Change from Baseline Homeostasis Model Assessment - Beta cells (HOMA2-B) at 12 weeks

    Percentage

    Time frame: 0 and 12 weeks.

  3. Change from Baseline Homeostasis Model Assessment - Insuline Resistance (HOMA2-IR) at 12 weeks

    Percentage

    Time frame: 0 and 12 weeks.

  4. Change from Baseline Fried frailty score at 6 and 12 weeks

    Level of frailty assessed by Fried Criteria. Intermediate or prefrail: 1 or 2 criteria present. Positive for frailty phenotype: ≥3 criteria present.

    Time frame: 0, 6 and 12 weeks.

  5. Change from Baseline Functional capacity at 6 and 12 weeks

    Level of functional capacity assessed by the test SPPB. Scores 0-3: Very low physical function; Scores 4-6: Low physical function; Scores 7-9: Moderate physical function; Scores 10-12: High physical function

    Time frame: 0, 6 and 12 weeks.

  6. Change from Baseline Disability at 6 and 12 weeks

    Level of disability assessed by the Barthel test. A participant scoring 0 points would be dependent in all assessed activities of daily living, whereas a score of 100 would reflect independence in these activities.

    Time frame: 0, 6 and 12 weeks.

  7. Functional mobility at 6 and 12 weeks

    Level of functional mobility assessed by the Lawton test. A scale from 0 to 8, expressing higher scores better levels of independence.

    Time frame: 0, 6 and 12 weeks.

  8. Change from Baseline Muscular power at 6 and 12 weeks

    Watts.

    Time frame: 0, 6 and 12 weeks.

  9. Change from Baseline Levels of strength at 6 and 12 weeks

    Load (kg).

    Time frame: 0, 6 and 12 weeks.

  10. Change from Baseline Bone Mineral Density at 12 weeks

    g/cm3

    Time frame: 0 and 12 weeks.

  11. Change from Baseline Pigment Epitelium Derived Factor (PEDF) at 12 weeks

    Circulating level of PDEF assessed by Western Blot.

    Time frame: 0 and 12 weeks.

  12. Genotyping of TCF7L2 (rs7903146)

    Assessed by Real-time PCR.

    Time frame: 0 week.

  13. Genotyping of TM6SF2 (rs10401969)

    Assessed by Real-time PCR.

    Time frame: 0 week.

  14. Genotyping of HLA (rs2854275)

    Assessed by Real-time PCR.

    Time frame: 0 week.

Secondary outcomes

  1. Change from Baseline Body Mass Index at 6 and 12 weeks

    Kg by square meters.

    Time frame: 0, 6 and 12 weeks.

  2. Change from Baseline Waist circumference at 6 and 12 weeks

    Meters.

    Time frame: 0, 6 and 12 weeks.

  3. Change from Baseline Blood pressure (systolic and diastolic) at 6 and 12 weeks

    mmHg.

    Time frame: 0, 6 and 12 weeks.

  4. Change from Baseline Concentration of Triglycerides at 12 weeks

    mg/dL.

    Time frame: 0 and 12 weeks.

  5. Change from Baseline Concentration of Total Cholesterol at 12 weeks

    mg/dL.

    Time frame: 0 and 12 weeks.

  6. Change from Baseline Concentration of HDL Cholesterol at 12 weeks

    mg/dL.

    Time frame: 0 and 12 weeks.

  7. Change from Baseline Concentration of LDL Cholesterol at 12 weeks

    mg/dL.

    Time frame: 0 and 12 weeks.

  8. Change from Baseline Subjective level of quality of life at 12 weeks

    Level of quality of life assessed by the test EuroQoL index, EQ-5D-5L. The score is the time trade-off (TTO). Scale from 11111 to 55555 being the higher the best health related quality of life.

    Time frame: 0 and 12 weeks.

  9. Change from Baseline Physical activity at 12 weeks

    Accelerometry, counts/min.

    Time frame: 0 and 12 weeks.

  10. Change from Baseline Balance at 12 weeks

    Level of balance assessed in a force platform. Newtons.

    Time frame: 0 and 12 weeks.

07

Study locations

1 site
  • Instituto Nacional de Educación Física
    Madrid, 28040, Spain
08

References and documents

Publications

  • Guadalupe-Grau A, Carnicero JA, Gomez-Cabello A, Gutierrez Avila G, Humanes S, Alegre LM, Castro M, Rodriguez-Manas L, Garcia-Garcia FJ. Association of regional muscle strength with mortality and hospitalisation in older people. Age Ageing. 2015 Sep;44(5):790-5. doi: 10.1093/ageing/afv080. Epub 2015 Jul 11. PubMed 26163682 ↗
  • Garcia-Garcia FJ, Carcaillon L, Fernandez-Tresguerres J, Alfaro A, Larrion JL, Castillo C, Rodriguez-Manas L. A new operational definition of frailty: the Frailty Trait Scale. J Am Med Dir Assoc. 2014 May;15(5):371.e7-371.e13. doi: 10.1016/j.jamda.2014.01.004. Epub 2014 Mar 2. PubMed 24598478 ↗
  • Garcia-Garcia FJ, Gutierrez Avila G, Alfaro-Acha A, Amor Andres MS, De Los Angeles De La Torre Lanza M, Escribano Aparicio MV, Humanes Aparicio S, Larrion Zugasti JL, Gomez-Serranillo Reus M, Rodriguez-Artalejo F, Rodriguez-Manas L; Toledo Study Group. The prevalence of frailty syndrome in an older population from Spain. The Toledo Study for Healthy Aging. J Nutr Health Aging. 2011 Dec;15(10):852-6. doi: 10.1007/s12603-011-0075-8. PubMed 22159772 ↗
  • Losa-Reyna J, Baltasar-Fernandez I, Alcazar J, Navarro-Cruz R, Garcia-Garcia FJ, Alegre LM, Alfaro-Acha A. Effect of a short multicomponent exercise intervention focused on muscle power in frail and pre frail elderly: A pilot trial. Exp Gerontol. 2019 Jan;115:114-121. doi: 10.1016/j.exger.2018.11.022. Epub 2018 Dec 4. PubMed 30528641 ↗
  • Alcazar J, Rodriguez-Lopez C, Ara I, Alfaro-Acha A, Rodriguez-Gomez I, Navarro-Cruz R, Losa-Reyna J, Garcia-Garcia FJ, Alegre LM. Force-velocity profiling in older adults: An adequate tool for the management of functional trajectories with aging. Exp Gerontol. 2018 Jul 15;108:1-6. doi: 10.1016/j.exger.2018.03.015. Epub 2018 Mar 20. PubMed 29567100 ↗
  • Alcazar J, Guadalupe-Grau A, Garcia-Garcia FJ, Ara I, Alegre LM. Skeletal Muscle Power Measurement in Older People: A Systematic Review of Testing Protocols and Adverse Events. J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):914-924. doi: 10.1093/gerona/glx216. PubMed 29309534 ↗
  • Alcazar J, Rodriguez-Lopez C, Ara I, Alfaro-Acha A, Manas-Bote A, Guadalupe-Grau A, Garcia-Garcia FJ, Alegre LM. The Force-Velocity Relationship in Older People: Reliability and Validity of a Systematic Procedure. Int J Sports Med. 2017 Dec;38(14):1097-1104. doi: 10.1055/s-0043-119880. Epub 2017 Nov 10. PubMed 29126339 ↗
  • Guadalupe-Grau A, Aznar-Lain S, Manas A, Castellanos J, Alcazar J, Ara I, Mata E, Daimiel R, Garcia-Garcia FJ. Short- and Long-Term Effects of Concurrent Strength and HIIT Training in Octogenarians with COPD. J Aging Phys Act. 2017 Jan;25(1):105-115. doi: 10.1123/japa.2015-0307. Epub 2016 Aug 24. PubMed 27402660 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individualised report to all the participants after the completion of the study.

Supporting information: Analytic code

Time frame: At the end of the intervention.

Access criteria: The participants who have accepted to have the report.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in May 2020, 4 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 4 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Apr 2, 2020
StartActual
Jan 15, 2020
Primary completionActual
May 15, 2020
CompletionEst.
Dec 21, 2021
Last update
Oct 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04332302
Lead sponsor
Technical University of Madrid
Collaborators
Spanish Society of Diabetes, University of Castilla-La Mancha, Castilla-La Mancha Health Service
Responsible party
Amelia Guadalupe Grau (Principal Investigator, Technical University of Madrid) — Principal investigator
First posted
Apr 2, 2020
Start date
Jan 15, 2020
Primary completion
May 15, 2020
Completion
Dec 21, 2021 (estimated)
Last update
Oct 19, 2020

Study contacts

Amelia Guadalupe Grau, PhD
principal investigator · Technical University of Madrid
Carmen Ramírez Castillejo, PhD
study chair · Technical University of Madrid
Marcela González Gross, Professor
study director · Technical University of Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion